Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.26|
|52 Week High||US$3.12|
|52 Week Low||US$9.67|
|1 Month Change||-6.59%|
|3 Month Change||-26.58%|
|1 Year Change||-35.83%|
|3 Year Change||-25.91%|
|5 Year Change||-63.33%|
|Change since IPO||-77.91%|
Recent News & Updates
Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk
Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics. AGT Corporation is in a reasonable financial position evidenced by 2+ years of cash runway driven by a low-cash burn (TTM: -$53M) and cash of $111M (March 2021). XLRP is being targeted by AGTC's lead therapeutic, RPGR, currently in a Phase 2/3 Vista study (data expected: 3Q 22) and a Phase 1/2 expansion trial known as Skyline (data expected: 4Q 21). In summary, the author projects Applied Genetic Technologies Corporation as a high-risk "hold".
|AGTC||US Biotechs||US Market|
Return vs Industry: AGTC underperformed the US Biotechs industry which returned 23.4% over the past year.
Return vs Market: AGTC underperformed the US Market which returned 30.7% over the past year.
Stable Share Price: AGTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AGTC's weekly volatility (7%) has been stable over the past year.
About the Company
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company’s advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease.
Is Applied Genetic Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGTC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGTC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AGTC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGTC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGTC is good value based on its PB Ratio (1.4x) compared to the US Biotechs industry average (3.1x).
How is Applied Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGTC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGTC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGTC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGTC's revenue (67.2% per year) is forecast to grow faster than the US market (9.5% per year).
High Growth Revenue: AGTC's revenue (67.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGTC's Return on Equity is forecast to be high in 3 years time
How has Applied Genetic Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGTC is currently unprofitable.
Growing Profit Margin: AGTC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGTC is unprofitable, and losses have increased over the past 5 years at a rate of 57% per year.
Accelerating Growth: Unable to compare AGTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: AGTC has a negative Return on Equity (-62.06%), as it is currently unprofitable.
How is Applied Genetic Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: AGTC's short term assets ($113.0M) exceed its short term liabilities ($16.6M).
Long Term Liabilities: AGTC's short term assets ($113.0M) exceed its long term liabilities ($16.1M).
Debt to Equity History and Analysis
Debt Level: AGTC's debt to equity ratio (10.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AGTC's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGTC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AGTC has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 35.5% each year.
What is Applied Genetic Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGTC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGTC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGTC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGTC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGTC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sue Washer (60 yo)
Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...
CEO Compensation Analysis
Compensation vs Market: Sue's total compensation ($USD988.25K) is above average for companies of similar size in the US market ($USD545.00K).
Compensation vs Earnings: Sue's compensation has been consistent with company performance over the past year.
Experienced Management: AGTC's management team is seasoned and experienced (17.5 years average tenure).
Experienced Board: AGTC's board of directors are considered experienced (8.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 65.8%.
Applied Genetic Technologies Corporation's employee growth, exchange listings and data sources
- Name: Applied Genetic Technologies Corporation
- Ticker: AGTC
- Exchange: NasdaqGM
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$139.381m
- Shares outstanding: 42.75m
- Website: https://www.agtc.com
Number of Employees
- Applied Genetic Technologies Corporation
- 14193 NW 119th Terrace
- Suite 10
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 04:32|
|End of Day Share Price||2021/09/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.